Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.32 |
| ▸ | MC3R | P41968 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.32 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.32 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14505651 | 0.74 | — | — | |
| SCHEMBL12650411 | 0.73 | ADORA2B (0.38) | ADORA2AADORA2BGAAALDH1A1LMNA | |
| SCHEMBL14981440 | 0.72 | ADORA2A (0.40) | ADORA2AADORA2BPOLBPIK3CDADORA3 | |
| SCHEMBL1783779 | 0.71 | MAOA (0.39) | ALDH1A1SMN1; SMN2KMT2ATSHRMAPK1 | |
| SCHEMBL1782387 | 0.69 | TSHR (0.39) | ADORA2AADORA2BGAASMN1; SMN2KMT2A | |
| SCHEMBL3284102 | 0.69 | PTGS1 (0.41) | ADORA2BCNR1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL3846149 | 0.69 | PDE4A (0.43) | ADORA2AADORA2BTDP1MAPTL3MBTL1 | |
| SCHEMBL1781515 | 0.68 | TP53 (0.48) | ADORA2AADORA2BPOLBADORA3ADORA1 | |
| SCHEMBL13547845 | 0.68 | GAA (0.38) | ADORA2AGAA | |
| SCHEMBL16116340 | 0.68 | GSK3A (0.50) | GAAPIK3CDADORA3ALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024220843-A1 | TECHNOLOGIES TARGETING CELL STATES | AURON THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| CN-107074823-B | Therapeutic compounds and uses thereof | 基因泰克公司 | 2021-05-04 | — | — | CN | disclosed |
| EP-3189046-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3189046-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10358437-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| US-10358437-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| US-10316023-B2 | — | — | 2019-06-11 | — | — | US | disclosed |
| US-10316023-B2 | — | — | 2019-06-11 | — | — | US | disclosed |
| EP-1856065-B1 | 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2009-11-11 | — | — | EP | disclosed |
| EP-1856065-B1 | 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2009-11-11 | — | — | EP | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
| US-6191130-B1 | HYPOTENSIVE AGENTS; THERAPY FOR SEXUAL DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2001-02-20 | — | — | US | disclosed |
| EP-0707571-B1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1997-05-02 | — | — | EP | disclosed |
| US-5591743-A | ANXIOLYTIC DRUGS OR HYPOTENSIVE AGENTS | PIERRE FABRE MEDICAMENT (FR) | 1997-01-07 | — | — | US | disclosed |
| EP-0707571-A1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001965-A1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PIERRE FABRE MEDICAMENT (FR) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316023-B2 | — | PKD1, NHERF1, PCSK6 | ADORA2A 4249/4885ADORA2B 2936/4885GAA 791/4885 |
| US-10358437-B2 | Therapeutic compounds and uses thereof | PKD1, NHERF1, HDAC10 | ADORA2A 3561/4885ADORA2B 2210/4885GAA 736/4885 |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | CBR3, NOX3, RTN3 | ADORA2A 2196/4885ADORA2B 1684/4885GAA 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.